Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,029 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,029 Papers indexed
1,440 Papers AI scored
40,029 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40029 results
B
Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020.
PMID 41501994 Published: 2026-01-09 Ingested: 2026-08-02 12:12 AM JNCI cancer spectrum
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 72.0; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 22.0; sample size: 30.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 42.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 52.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Management outcomes of prolactinoma: a retrospective study from Southern Iraq.
PMID 41178903 Published: 2025-09-01 Ingested: 2026-08-02 12:05 AM Journal of medicine and life
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 42.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Asparaginase Premedication With Hydrocortisone Decreases Hypersensitivity Reactions.
PMID 40928245 Published: 2025-09-10 Ingested: 2026-08-02 12:05 AM Journal of pediatric hematology/oncology
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 52.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Life Milestone Achievement Among Young Adult Childhood Cancer Survivors: A Population-Based Cohort and Matched Case-Control Study.
PMID 40827033 Published: 2025-08-18 Ingested: 2026-08-02 12:04 AM Pediatric blood & cancer
AI -
Standard 74.4
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 32.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 417 of 3336
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic